Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Purchases $12,910.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson purchased 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The stock was bought at an average price of $12.91 per share, for a total transaction of $12,910.00. Following the transaction, the vice president now directly owns 264,148 shares of the company’s stock, valued at $3,410,150.68. This trade represents a 0.38 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Greenwich LifeSciences Trading Up 2.9 %

GLSI opened at $14.35 on Wednesday. The company has a market cap of $188.70 million, a P/E ratio of -17.94 and a beta of 1.62. The company’s 50 day moving average is $13.80 and its 200-day moving average is $14.43. Greenwich LifeSciences, Inc. has a 1-year low of $8.00 and a 1-year high of $21.44.

Institutional Trading of Greenwich LifeSciences

A number of hedge funds have recently added to or reduced their stakes in GLSI. Rhumbline Advisers acquired a new position in shares of Greenwich LifeSciences during the second quarter worth $117,000. Vanguard Group Inc. grew its position in Greenwich LifeSciences by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock worth $4,449,000 after acquiring an additional 1,420 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Greenwich LifeSciences in the 2nd quarter worth about $264,000. Barclays PLC raised its position in Greenwich LifeSciences by 323.3% in the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after purchasing an additional 6,538 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Greenwich LifeSciences by 4.6% in the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after purchasing an additional 5,861 shares during the last quarter. Institutional investors and hedge funds own 4.16% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright increased their price objective on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.